Progression-free survival overused for cancer drug approvals, oncologists warn
The term is 'misleading' to patients as many equate it with overall survival, doctors argue.
Progression-free survival is a poor surrogate for overall survival and should not be relied upon as a primary endpoint for registration and marketing of anticancer drugs, according to Canadian oncologists.
The use of progression-free survival (PFS) remains debated despite being the most common primary endpoint in oncology trials, the research team led by Queen’s University in Ontario said.
